Extrapyramidal side-effects of antipsychotics in a randomised trial

Del D. Miller, Stanley N. Caroff, Sonia M. Davis, Robert A. Rosenheck, Joseph Patrick McEvoy, Bruce L. Saltz, Silvana Riggio, Miranda H. Chakos, Marvin S. Swartz, Richard S.E. Keefe, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Background There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Alms To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted. Results There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing secondgeneration antipsychotics with perphenazine or comparing between second-generation antipsychotics. secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalBritish Journal of Psychiatry
Volume193
Issue number4
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Perphenazine
Antipsychotic Agents
Psychomotor Agitation
Risperidone
Incidence
Parkinsonian Disorders
Schizophrenia
Dystonia
Pharmaceutical Preparations
Quetiapine Fumarate

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., ... Lieberman, J. A. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry, 193(4), 279-288. https://doi.org/10.1192/bjp.bp.108.050088

Extrapyramidal side-effects of antipsychotics in a randomised trial. / Miller, Del D.; Caroff, Stanley N.; Davis, Sonia M.; Rosenheck, Robert A.; McEvoy, Joseph Patrick; Saltz, Bruce L.; Riggio, Silvana; Chakos, Miranda H.; Swartz, Marvin S.; Keefe, Richard S.E.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: British Journal of Psychiatry, Vol. 193, No. 4, 01.10.2008, p. 279-288.

Research output: Contribution to journalArticle

Miller, DD, Caroff, SN, Davis, SM, Rosenheck, RA, McEvoy, JP, Saltz, BL, Riggio, S, Chakos, MH, Swartz, MS, Keefe, RSE, Stroup, TS & Lieberman, JA 2008, 'Extrapyramidal side-effects of antipsychotics in a randomised trial', British Journal of Psychiatry, vol. 193, no. 4, pp. 279-288. https://doi.org/10.1192/bjp.bp.108.050088
Miller, Del D. ; Caroff, Stanley N. ; Davis, Sonia M. ; Rosenheck, Robert A. ; McEvoy, Joseph Patrick ; Saltz, Bruce L. ; Riggio, Silvana ; Chakos, Miranda H. ; Swartz, Marvin S. ; Keefe, Richard S.E. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Extrapyramidal side-effects of antipsychotics in a randomised trial. In: British Journal of Psychiatry. 2008 ; Vol. 193, No. 4. pp. 279-288.
@article{2a2d9a686f1d4387ad18b918aad4d1c6,
title = "Extrapyramidal side-effects of antipsychotics in a randomised trial",
abstract = "Background There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Alms To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted. Results There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing secondgeneration antipsychotics with perphenazine or comparing between second-generation antipsychotics. secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.",
author = "Miller, {Del D.} and Caroff, {Stanley N.} and Davis, {Sonia M.} and Rosenheck, {Robert A.} and McEvoy, {Joseph Patrick} and Saltz, {Bruce L.} and Silvana Riggio and Chakos, {Miranda H.} and Swartz, {Marvin S.} and Keefe, {Richard S.E.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1192/bjp.bp.108.050088",
language = "English (US)",
volume = "193",
pages = "279--288",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "4",

}

TY - JOUR

T1 - Extrapyramidal side-effects of antipsychotics in a randomised trial

AU - Miller, Del D.

AU - Caroff, Stanley N.

AU - Davis, Sonia M.

AU - Rosenheck, Robert A.

AU - McEvoy, Joseph Patrick

AU - Saltz, Bruce L.

AU - Riggio, Silvana

AU - Chakos, Miranda H.

AU - Swartz, Marvin S.

AU - Keefe, Richard S.E.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Alms To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted. Results There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing secondgeneration antipsychotics with perphenazine or comparing between second-generation antipsychotics. secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

AB - Background There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Alms To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted. Results There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing secondgeneration antipsychotics with perphenazine or comparing between second-generation antipsychotics. secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=53949112680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53949112680&partnerID=8YFLogxK

U2 - 10.1192/bjp.bp.108.050088

DO - 10.1192/bjp.bp.108.050088

M3 - Article

C2 - 18827289

AN - SCOPUS:53949112680

VL - 193

SP - 279

EP - 288

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 4

ER -